Aveo’s cancer drug circles the drain after a scuttled Phase II trial

Damian Garde

Aveo Oncology and Astellas Pharma are shutting down a II study of tivozanib in breast failing to enroll enough patients, the partners announced.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS